Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Holderried, Tobias
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy	Recruiting	3	210	Europe	MC0518, BAT	medac GmbH	Steroid-refractory Acute Graft-versus-host Disease	08/27	08/30
PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial)	Recruiting	2	387	Europe	Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo	MaaT Pharma	Transplant Complication	10/26	02/27
ACTengine, NCT03686124 / 2019-002370-31: ® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors ORR data from ACTengine trial for solid tumors Nov 2021 - Nov 2021: ORR data from ACTengine trial for solid tumors Initial data from dose expansion trial for r/r solid tumors Mar 2021 - Mar 2021: Initial data from dose expansion trial for r/r solid tumors	Recruiting	1	476	Europe, US	IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, nivolumab (Opdivo®), Opdivo®, IMADetect®	Immatics US, Inc., Immatics US Inc	Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer	12/28	12/28